Presentation by Inspire CEO Brian Loew to the Patient-Centered Technologies for Post-Marketing and Real World Data conference

1. How e-Patients are
Learning and Sharing
Information about
Pre-Approval Therapies
brian@inspire.com
@teaminspire
Patient-Centered Technologies for Post-Marketing and Real World Data Research
February 6, 2014
Brian Loew, CEO, Inspire
www.Inspire.com
Thursday, February 13, 14

2. Patients are increasingly seeking and sharing information
online about drugs before FDA approval
Examples from our ovarian, lung, prostate and advanced breast cancer groups:
• “About temsirolimus: Right after my cancer returned 3 months after the completion of the taxol-platinum
regimen, my doctor sent me to the U of Penn to enroll in a study...I was delighted to find that it was reducing the
size of my tumor, though it never completely eliminated it.”
• “If the resistance to Tarceva is due to the T790M mutation, there are two promising drugs in clinical trials right
now. One is from Clovis called CO-1686, the other from AstraZeneca called AZD9291.”
• “Nivolumab 3mg/kg every 2 weeks HAS worked for me one tumor so small no longer measurable. I knew it was
working as I just felt better almost immediately.”
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com

3. More sharing–driven entirely by engaged, insightful patients:
• “The phase 3 trial that is just starting is using Mekinist, which is FDA approved for Melanoma. Your
doc should make a case to your insurance to cover this drug for your treatment and start you on it
outside of the trial.”
• “There is a drug in prostate cancer that targets CLTA-4 in clinical trials.”
• “When deciding between continuing on anti-PD1 trial or switching to chemotherapy, I think you
need to consider at least two things: 1) What is the response rate for the chemotherapy you'd
receive as 3rd(?) line treatment? 2) Many of the immunotherapy clinical trials have an exclusion if
you've had any prior immunotherapy treatment.”
• “I would try (bazedoxifene) in a heartbeat if current treatment tamoxifen fails and I could get it.”
• “My onc is at the Cleveland Clinic and just offered (Torisel) to me. He gave me the choice of avastin
and three other drugs. He thought that temsirolimus would be the best choice along with avastin.”
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com

4. Discovery
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com

5. Discovery
When someone recently started a discussion about privacy issues, I got a little concerned that too
much privacy might have prevented me from finding what has been the most useful, supportive
group for me.
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com

6. The “Tarceva Diva,” and her Divas & Dudes
• In Inspire’s Lung Cancer Survivors Support Community, one now-deceased member,
“MarieZee100,” began a discussion topic--on her own--to connect people who are or were on
Tarceva
• In just her “Tarceva Divas” discussion strings alone, apx. 8,000 posts by members, over apx. 30
months
• Discussed not just Tarceva itself, but new drugs and combination therapies
• Strength of self-organized “sub-community”--MarieZee100 has died of lung cancer, but another
member picked up the “Tarceva Diva” mantle, and the discussion topic continues stronger than
ever.
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com

7. A rare disease patient’s story
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com

8. Discovery, as a community finds itself
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com

9. Rare disease e-patients’ call to action
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com

10. Takeaways:
Patients are engaged in seeking and sharing detailed
information about pre-approval therapies.
Many patients want to contribute to research.
Technology matters a great deal.
Technology doesn’t matter at all.
Brian Loew, brian@inspire.com, @teaminspire
Thursday, February 13, 14
www.Inspire.com